Vir Biotechnology Balance Sheet
NASDAQ: VIRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vir Biotechnology financial position
At the end of fiscal 2025, Vir Biotechnology reported total assets of $1.00 billion, down 28.3% from a year earlier against total liabilities of $237.5 million. Shareholders' equity stood at $765.3 million, or 76.3% of assets. The company held $232.2 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 5.54, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Vir Biotechnology balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 232.19M | 222.95M | 241.58M | 848.63M | 347.81M | 436.57M | 109.33M | 47.60M | 187.92M |
| Short-Term Investments | 228.75M | 678.05M | 1.27B | 1.52B | 217.18M | 300.29M | 274.10M | 50.84M | — |
| Receivables | — | — | — | 0 | 773.08M | 0 | — | — | — |
| Total Current Assets | 514.08M | 1.04B | 1.59B | 2.52B | 1.56B | 772.37M | 403.00M | 117.78M | — |
| Property, Plant & Equipment | 55.62M | 63.18M | 96.02M | 105.61M | 42.83M | 17.95M | 16.31M | 12.29M | — |
| Goodwill | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | — |
| Intangible Assets | 7.85M | 8.12M | 22.57M | 32.76M | 33.29M | 33.82M | 35.69M | 36.92M | — |
| Long-Term Investments | 314.57M | 190.01M | 105.28M | 23.93M | 201.39M | 0 | 24.29M | — | — |
| Total Assets | 1.00B | 1.40B | 1.92B | 2.80B | 1.95B | 918.76M | 512.07M | 191.60M | — |
| Accounts Payable | 9.80M | 5.08M | 6.33M | 6.42M | 6.52M | 5.08M | 5.88M | 6.47M | — |
| Total Current Liabilities | 92.81M | 119.66M | 175.41M | 511.03M | 341.24M | 99.06M | 59.21M | 39.91M | — |
| Total Liabilities | 237.55M | 248.43M | 328.82M | 724.13M | 522.42M | 201.91M | 88.13M | 61.64M | — |
| Shareholders' Equity | 765.28M | 1.15B | 1.59B | 2.08B | 1.43B | 716.85M | 423.94M | -179.18M | -68.92M |
| Retained Earnings | -1.20B | -759.78M | -237.82M | 377.24M | -138.60M | -667.18M | -368.52M | -193.84M | — |
| Net Cash (Debt) | 460.94M | 901.00M | 1.51B | 2.37B | 565.00M | 736.86M | 383.44M | 98.44M | 187.92M |
| Shares Outstanding | 139.47M | 136.96M | 134.78M | 133.24M | 131.16M | 127.42M | 107.65M | 8.86M | — |
This table shows 9 annual periods of Vir Biotechnology's balance sheet, from FY 2025 back to FY 2017, across 16 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow VIR's reporting calendar. What is a balance sheet?